Trevena to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021 07:00 ET | Trevena Inc.
CHESTERBROOK, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Reports Second Quarter 2021 Results
August 12, 2021 07:00 ET | Trevena Inc.
Company reaffirms YE goal of 100 formulary wins OLINVYK respiratory physiology study currently enrolling, topline data expected by YE 2021 NIH / Vanderbilt University Medical Center-led...
Trevena Announces NIH Has Resumed Recruiting Patients in Proof-of-Concept Study for TRV734 in Opioid Use Disorder
June 16, 2021 07:00 ET | Trevena Inc.
-- TRV734 reduced drug-seeking behavior in a preclinical model of relapse, suggesting its utility as a novel oral maintenance treatment for opioid use disorder The study is being conducted and...